Inhibrx Biosciences Inc.
INBX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.81B
Close$
$0.80
99.3% downside
Current Fair Value
99.3% downsideOvervalued by 99.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.81 Billion |
|---|---|
| Enterprise Value | $1.68 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-9.04 |
| Beta | 3.52 |
| Outstanding Shares | 15,669,000 |
Return
| Return on Equity | 260.83% |
|---|---|
| Return on Assets | -89.60% |
| Return on Invested Capital | -100.40% |
Valuation & Multiples
| P/E Ratio | -13.9 |
|---|---|
| PEG | -49.8 |
| Price to Sales | - |
| Price to Book Ratio | -30.29 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -13.28 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | -0.1 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$-1.90
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-2.45
Average shareholder expectationRevenue Estimate
$1.90 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1470▲ 10.48% |
|---|---|
| Total Calls | 328,500▼ 9.88% |
| Total Puts | 48,300▲ 213.64% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 96.80%▲ 15.23% |
|---|---|
| Total Invested | $1.37B▲ 60.01% |
| Investors Holding | 178▲ 31.00% |
ESG Score
No data
About Inhibrx Inc
88 employeesInhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the spe...